Individual skill

jama-oncology

Use when targeting JAMA Oncology or deciding whether a clinical-oncology study fits this venue. Encodes the journal's fit, the cancer-trial and outcomes-research evidence bar, reporting-guideline and trial-registration requirements, JAMA Network house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice.

Clinical-Medicine-Journal-Skills/skills/jama-oncology/SKILL.md

Read pinned source

Source commit 932eb23331721b16e967c59f093781be1928b498

What was checked

Matches the observed repository HEAD
Yes
Scanner rules are current
Yes
Repository scan complete
No
Skill scan complete
Yes
Observed behavior
Network or broad shell
Last checked
Nov 9, 2026

These are observations at the recorded commit, not a guarantee of safety. Review the source before running it.

Install this skill

Choose an agent in your Stack or copy a command below. Commands fetch the pinned commit and copy only this skill directory. Existing destinations are refused. Copying a command does not install anything.

An install command is unavailable: current rules, complete repository and skill scans, an eligible behavior level and a permitted license are required.

Repository context

Repository stars (not skill ratings)
1,404
Repository last updated
Sep 27, 2026
License
MIT

Observed agent integration: No specific integration evidence. Standard SKILL.md installation does not imply verified compatibility.

Files and excerpt

File metadata and permitted, redacted excerpts come from the recorded scan. Source links are pinned to that commit.

Browse files
Read excerpt

# JAMA Oncology (jama-oncology)

## Journal positioning

JAMA Oncology is a JAMA Network specialty journal for clinical and translational
oncology research aimed at a broad cancer-care readership — medical, surgical, and
radiation oncologists, as well as cancer-epidemiology and outcomes researchers. It
favors practice-relevant work: randomized cancer trials, comparative-effectiveness and
real-world outcomes analyses, screening and prevention studies, and biomarker work tied
to a clinically meaningful endpoint. It is positioned as a general oncology venue with
JAMA's emphasis on absolute benefit, toxicity, and patient-centered outcomes, distinct
from a society flagship such as Annals of Oncology (ESMO). Single-arm early-phase
reports with no comparator, descriptive molecular series, and surrogate-only signals
with weak clinical translation are a weak fit. This skill is a **fit /
Back to top